Kidney Precision Medicine Project Central Hub (U24 Clinical Trial Not Allowed)

The Kidney Precision Medicine Project Central Hub is a federal funding opportunity administered by the National Institutes of Health within the U.S. Department of Health and Human Services. This initiative is part of a broader national effort to advance understanding of kidney disease through precision medicine approaches. The program is structured as a cooperative agreement, indicating substantial involvement from the funding agency in guiding and collaborating on project activities. The Central Hub is intended to serve as the operational and scientific backbone of the Kidney Precision Medicine Project, coordinating multiple research efforts and ensuring alignment with the program’s overarching goals. The primary purpose of this funding opportunity is to establish a Central Hub that will lead a unified scientific and operational effort to identify and define new pathways and subgroups of acute and chronic kidney disease. These discoveries are expected to enable the development of precision clinical trials tailored to specific patient populations. The Central Hub will oversee and integrate advanced computational analyses, large-scale data management and sharing systems, communication strategies, and administrative functions. The project emphasizes open science principles, requiring all participating personnel to contribute actively to collaborative discovery and transparent data dissemination. Funding under this opportunity is expected to support a wide range of activities necessary to maintain and advance the Central Hub’s functions. These include infrastructure for data coordination, bioinformatics analysis, stakeholder engagement, and project management. While specific allowable and unallowable costs are detailed in the full announcement, the overall funding scope is designed to support a comprehensive, multi-functional hub capable of sustaining a complex, multi-institutional research initiative. There is no cost sharing or matching requirement associated with this funding opportunity, which reduces financial barriers for eligible applicants. Eligibility for this program is broad and inclusive of a variety of U.S.-based entities. Eligible applicants include state and local governments, public and private institutions of higher education, nonprofit organizations with or without 501(c)(3) status, small and large for-profit organizations, and tribal governments and organizations. However, foreign organizations and non-U.S. components of U.S. organizations are explicitly excluded from applying. This ensures that the program remains focused on domestic research infrastructure and collaboration. Additional eligibility requirements and clarifications are provided in the full Notice of Funding Opportunity. The application process requires submission through the appropriate federal grants systems, typically involving registration with Grants.gov and compliance with NIH submission protocols. Applicants are expected to prepare a comprehensive proposal detailing their technical approach, organizational capacity, and plans for collaboration and data sharing. While specific application components are outlined in the full announcement, they generally include scientific plans, budgets, biosketches, and institutional support documentation. Evaluation criteria will likely focus on scientific merit, organizational capability, and alignment with the goals of the Kidney Precision Medicine Project. The timeline for this opportunity is clearly defined, with applications opening upon the posted date of June 3, 2026, and closing on July 10, 2026. This represents a relatively short application window, requiring applicants to prepare materials efficiently. Only one award is expected to be made, with an estimated total program funding of $5,000,000. The award period and notification timeline are not explicitly stated in the provided summary but are typically detailed in the full announcement. Interested applicants are encouraged to contact the Division of Kidney, Urologic, and Hematologic Diseases at the provided email address for additional information or clarification.